Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Johanna Roberts, Executive Vice President, General Counsel & Secretary at Penumbra Inc (NYSE:PEN), sold 520 shares of the company’s common stock on July 1, 2025. The sales were executed at prices ranging from $247.61 to $255.72, resulting in a total transaction value of $151,621.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan. Following the transactions, Roberts directly owns 66,057 shares of Penumbra.
In other recent news, Penumbra has reported strong financial results, showcasing a significant year-over-year growth in both sales and earnings per share (EPS). The company’s sales reached $324.1 million, a 16.3% increase from the previous year, while EPS surged to $0.83, surpassing Wall Street estimates. UBS analyst Priya Sachdeva increased the price target for Penumbra shares to $330, maintaining a Buy rating, reflecting confidence in the company’s growth trajectory. Stifel analyst Matthew Blackman also raised the price target to $318, highlighting the company’s robust performance in the U.S. market. BTIG analyst Ryan Zimmerman updated the price target to $320, noting Penumbra’s strong position in the market with its non-elective procedures and domestic manufacturing base.
In addition, Piper Sandler analyst Matt O’Brien has indicated that Penumbra’s Thunderbolt product might receive regulatory approval sooner than expected, which could provide a substantial boost to the company’s revenue. Penumbra’s management has confirmed high-level guidance metrics, including gross margins, and has raised U.S. Thrombectomy guidance, suggesting potential for further positive revisions. Investors are closely monitoring the potential early approval of the Thunderbolt device, which could offer Penumbra a competitive edge in the medical device sector. These developments reflect the market’s optimism about Penumbra’s growth prospects and strategic focus.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.